BERLIN (dpa-AFX) - Specialty pharma company Medios is facing the start of a difficult year due to stricter price regulation for certain drugs. In 2022, the company should have reached its targets. In 2023, the Berlin-based company was "missing" about 6.6 million euros in earnings before interest, taxes, depreciation and amortization (adjusted Ebitda) compared to 2022, company CEO Matthias Gärtner said in an interview with financial news agency dpa-AFX. "We have to think about what measures we can take to make up for that. To add to that will be difficult, but not impossible." In the medium term, the manager is counting on a broader positioning, acquisitions and expansion abroad. Currently, Medios is still fine-tuning its strategy, Gärtner said.

Thanks in part to these measures, Medios aims to increase operating profit more than sales in the medium term. "That is precisely our focus," Gärtner assured. He is confident that he will be able to "at least keep up" with the expected strong market growth in the coming years./tav/stw/mis